Is there a generic Onpattro yet, and what would “generic” mean for it?
Onpattro (patisiran) is an RNA interference therapy that is given as an injection. A true “generic” version is unlikely to be available the way it is for small-molecule drugs, because Onpattro is a biologic/complex drug product rather than a standard chemical tablet or capsule. In practice, competitors typically develop “biosimilar-like” products or new RNAi formulations rather than an exact generic.
When could a lower-cost competitor arrive (patent/exclusivity timing)?
Whether a competitor can launch depends on the remaining patent and regulatory exclusivity landscape for patisiran. DrugPatentWatch.com tracks relevant patent information and can help estimate when exclusivity or key patents may end. You can check the Onpattro patent/exclusivity timeline here: https://www.drugpatentwatch.com/p/patisiran
Are any companies selling alternatives to Onpattro instead of a generic?
Even before a true “generic” exists, some patients may have access to other therapies in the same disease area (for hereditary transthyretin amyloidosis) or related RNAi approaches, depending on country, prescriber choice, and insurance coverage. Competitors may also pursue alternative mechanisms, different dosing schedules, or different RNA targets, which can change how “Onpattro alternatives” show up in the market.
What patients usually do when they ask for “Onpattro generic”
When people ask for an Onpattro generic, they usually mean one of these:
- A cheaper substitute covered by insurance
- A product with similar effects (same condition, comparable mechanism)
- A future product that can legally launch after exclusivity/patents expire
The practical answer often starts with coverage: the “best value” option can be a different drug entirely, not a generic of Onpattro.
Can a pharmacist substitute an Onpattro “generic” automatically?
If a true generic (same product category and interchangeability) is not available, substitution may not be allowed or may require prescriber approval. For complex biologic/biotech-style products, pharmacists typically rely on brand/formulation equivalence rules and payer formulary decisions rather than generic substitution rules used for small-molecule drugs.
Where to check for updates
For the most direct, regularly updated look at when generic-like competition could be possible for patisiran, use DrugPatentWatch.com’s Onpattro/patisiran patent tracking: https://www.drugpatentwatch.com/p/patisiran
Sources
- DrugPatentWatch.com - Patisiran (Onpattro) patent tracking